Monitor for the effectiveness of the S-1 and subsequent trading of units (SCQCU). Key catalysts will be any definitive business combination announcement within the 12-month window. The high founder share dilution (25% vs typical 20%) and management's mixed track record (multiple liquidations) warrant caution.
Executive Summary
SPACCircle Acquisition Corp. filed Amendment No. 2 to its S-1 registration statement for a $150 million SPAC IPO. The company is a blank-check entity targeting digital assets, technology, and healthcare sectors. The offering consists of 15 million units at $10.00 each, each comprising one Class A ordinary share, one warrant (exercisable at $11.50), and one right to receive 1/3 of a Class A share upon a business combination. The sponsor purchased founder shares at ~$0.004 each, creating significant dilution for public investors (98.7% dilution at IPO). The company has 12 months (extendable to 15) to complete a business combination or will liquidate.
Key Financial Metrics
Key Facts
- IPO of 15,000,000 units at $10.00/unit for gross proceeds of $150,000,000
- Each unit consists of one Class A ordinary share, one warrant ($11.50 exercise price), and one right to receive 1/3 Class A share
- Sponsor paid $25,000 for 5,750,000 founder shares (~$0.004/share), resulting in 98.7% dilution for public shareholders
- Sponsor will purchase 254,090 private placement units for $2,540,900 in a concurrent private placement
- $150,000,000 of proceeds will be deposited in a trust account; ~$790,000 available for working capital outside trust
- Company has 12 months (or 15 months if definitive agreement announced) to complete a business combination or will liquidate
- Targeting digital assets, technology, and healthcare industries with a generalist approach
- Management team has prior SPAC experience including liquidations and completed business combinations (AvePoint, Grid Dynamics)
- Company had $60,451 cash and $175,984 working capital deficiency as of April 30, 2026; going concern qualification from auditors
- Founder shares represent 25% of post-IPO shares (higher than typical 20% for SPACs)
Financial Impact
IPO raises $150M in trust with $2.54M private placement; sponsor's $25K investment yields 5.75M shares creating massive dilution
Risk Factors
- No target identified; may fail to complete business combination within 12-15 months leading to liquidation
- Massive dilution: public shareholders experience 98.7% dilution at IPO due to sponsor's nominal cost basis
- Management team has history of SPAC liquidations (Enterprise 4.0, BioPlus, Epiphany, Carney, E.Merge)
- Going concern qualification from auditors due to working capital deficiency
- Conflicts of interest: management has fiduciary duties to other SPACs (SSAC, FORL, CHAR, PGAC, SSEA, FMAC) that may receive priority deal flow
- Only $790K available for operations outside trust; may need additional loans from sponsor
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001185185-26-004687 |
| Document: 0001185185-26-004687-index-headers.html | 0001185185-26-004687 |
| Document: 0001185185-26-004687-index.html | 0001185185-26-004687 |
| Document: 0001185185-26-004687.txt | 0001185185-26-004687 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | S-1/A | — | awaiting T+20 | — | — |
Oct 9, 2026 16d ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers